Study
Bryan Johnson’s Biomarkers: The Science and Limits of Biological Age
CRITIC REVIEW: Niko Hems says Johnson’s N=1 stack cannot isolate causes, and that epigenetic-age changes are surrogate signals rather than proven clinical endpoints; the page was updated 2 September.
YEARS lists Niko Hems, M.Sc. as author of a Bryan Johnson biomarker review first published 20 April 2026 and updated 2 September 2026. Hems describes Johnson’s use of blood panels, imaging, functional tests and epigenetic clocks, then separates measurement from clinical meaning. The review argues that a single-person protocol cannot identify which intervention among diet, exercise, sleep, supplements and other changes caused a result. It also flags confounding, the Hawthorne effect and the surrogate-endpoint problem: a lower epigenetic-age estimate is not proof of fewer heart attacks, disability or deaths. The article presents grip strength and VO₂ max as more outcome-proximal predictors than DNA-methylation clocks, while still treating them as predictors rather than randomized evidence. It cites older population studies and lifestyle trials, including CALERIE, but it is not a new trial and does not provide a new ingredient-specific efficacy result. The page’s update date places it in this week’s monitoring window, while its original publication date remains April. It supports cautious interpretation of Johnson’s claims and does not justify an evidence-grade upgrade.
An isolated biomarker value without clinical context ... is at best uninteresting and at worst misleading.
No new critic response from Peter Attia, Charles Brenner, Andrew Steele, an endocrinologist, or Time/NYT/Bloomberg/Atlantic was found in the 2–9 September window. This review itself supplies no ingredient-grade upgrade.
Cited by
1 encyclopedia entries reference this study.